DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 32,498 Shares

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DexCom Price Performance

DXCM stock traded down $0.65 during trading on Tuesday, hitting $70.70. The company had a trading volume of 2,603,968 shares, compared to its average volume of 3,881,061. The firm has a market capitalization of $27.63 billion, a price-to-earnings ratio of 49.44, a P/E/G ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average of $83.82 and a 200 day moving average of $76.94. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have weighed in on DXCM shares. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new stake in DexCom in the fourth quarter worth about $25,000. Private Trust Co. NA raised its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares during the period. Optiver Holding B.V. acquired a new stake in DexCom during the 4th quarter worth about $33,000. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Finally, Larson Financial Group LLC raised its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.